trial · primary record
Ritlecitinib 50 mg
Chronic Spontaneous Urticaria
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 200 |
| Primary completion | 2027-04-23 |
| Primary endpoint | Change from baseline in Urticaria Activity Score 7 (UAS7) at Week 12 |
| Registry ID | NCT07219615 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:53.529Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07219615
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.